Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Orthomimetics expands board of directors


Cambridge UK, 30 June 2009

Orthomimetics, the Cambridge-based developer of products for regenerative medicine, has appointed Patrick West, former Global Vice President of Sales and Marketing at Stryker Biotech, to its Board of Directors.

During an eight-year tenure as Global VP of Sales and Marketing for Stryker Biotech, Patrick was responsible for the development and management of a global sales force for Strykerís first-in-class bone morphogenetic protein product. Prior to this appointment, he had been an award-winning sales representative for Strykerís Endoscopy division, and held responsibility for the development and market expansion activities in the Instruments division. Subsequent to his experience with Stryker, Patrick founded and served as CEO of MaxTorque LLC, a company operating in the oil and gas space. Under Patrickís guidance, MaxTorque achieved industry-leading revenue and profit growth that culminated in the recent acquisition of the company by a strategic partner.

Commenting on the appointment, Andrew Lynn, CEO of Orthomimetics said: ďPatrick brings a unique combination of large orthopaedic company and successful entrepreneurial experience to the table. This is particularly important as we turn our focus to the controlled launch of our flagship product, Chondromimetic and consider global commercial opportunities. Patrick has already made a significant contribution to Orthomimetics through his work as a Senior Commercial Advisor and we are very pleased to deepen this relationship by welcoming him to the Board.Ē

With regulatory approval for Chondromimetic received for Europe in December 2008, a clinical development program already underway and negotiations for European distribution in progress, OM is now looking to build its commercial links with markets worldwide.

Editorís Notes:

Orthomimetics Limited is a medical technology company specialising in the design, development and manufacture of regenerative medical implants and minimally invasive delivery systems for the treatment of sports injuries, trauma and other conditions that affect knees, ankles and other articular joints. Formed in 2005 as the first spin-out venture from the Cambridge-MIT Institute, the company is bringing to market a line of medical device products designed to improve the treatment outcome of first-line surgical procedures for the regenerative repair of articular cartilage, meniscus, ligament and tendon injuries using natural biomaterials. These products are engineered to be compatible with existing surgical techniques and to work in combination with emerging cell- and biologics-based products.

For further information on Orthomimetics please go to our website: www.orthomimetics.com or contact Katherine Webster: info@orthomimetics.com


Publisher Contact Information:

OrthoMimetics Ltd. (OM)
-
info@orthomimetics.com

Company profile of OrthoMimetics Ltd. (acquired by Tigenix)
Past press releases of OrthoMimetics Ltd. (acquired by Tigenix) .

Data


27,722
Tech investments
From our Online Data Service
17,881
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Dec 21€50.0MKnowledge management
Dec 20€16.0MSemiconductors
Dec 17€18.0MOther Computers & Electronics
Dec 17€5.2MBiotechnology
Dec 17€17.0MBusiness applications
Dec 15€17.0ME-Commerce
Dec 4€3.3MNanotechnology

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Sep 30
TetaVi
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Mar 31
CompPair
the fit allocates chf 100'000 to comppair technologies

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.